Halozyme Therapeutics, Inc. (HALO) Deep Dive Video
Summary
A best-in-class, asset-light royalty “biotech utility” powering the global shift from IV to subcutaneous biologics—while racing to extend its moat beyond the 2027/2029 patent cliff with Wave 3 hyperconcentration tech.